Transcarent plans to acquire Accolade for $7.03 per share in cash in the second quarter of 2025, according to a Jan. 8 news release.
The deal is being financed by General Catalyst and Glen Tullman’s 62 Ventures. Upon completion, Accolade will become a privately held company and its common stock will no longer be listed on Nasdaq.
The transaction is expected to bring Transcarent’s generative AI-powered WayFinding and comprehensive care experiences, including pharmacy benefits, together with Accolade’s personalized healthcare platform and expertise in advocacy, expert medical opinions, and primary care.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.